Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-19 of 19 for your search:
Cancer Type/Condition:
Wilms tumor
Stage/Subtype:
recurrent Wilms tumor and other childhood kidney tumors
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer
Phase:
Phase IV
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and under
Sponsor:
NICHD
Protocol IDs:
PPRU 10762
, NCT00491946
2.
Phase I/II Study of Donor Lymphocyte Infusion in Patients With Persistent, Relapsed, or Progressing Malignancy After Nonmyeloablative Allogeneic Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
FHCRC-1803.00
, 5606, NCT00068718
3.
Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
BMT 0499 Solid
, NCT00179816
4.
Phase I/II Study of Dasatinib in Combination With Ifosfamide, Carboplatin, and Etoposide Phosphate in Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 25
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CHNMC-07053
, 07053, CA180 121, NCT00788125
5.
Phase II Study of Conditioning Regimen Comprising Anti-thymocyte Globulin, Clofarabine, and Rituximab in Patients With Primary or Secondary Graft Failure After Hematopoietic Stem Cell Transplantation
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
NCI
Protocol IDs:
UMN-2007LS072
, UMN-2007LS072, UMN-MT2007-07, NCT00617929
6.
Trial Of Double Umbilical Cord Blood Transplantation
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
65 and under
Sponsor:
Other
Protocol IDs:
umcc 2007.137
, HUM00017515, NCT00763490
7.
Phase II Study of Cixutumumab in Patients With Relapsed or Refractory Solid Tumors
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
6 months to 30 years
Sponsor:
NCI
Protocol IDs:
COG-ADVL0821
, ADVL0821, NCT00831844
8.
Phase I Study of Ixabepilone in Young Patients With Refractory Solid Tumors (Closed to Accrual as of 10/4/2007) or Relapsed or Refractory Leukemia
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
2 to 21
Sponsor:
NCI
Protocol IDs:
NCI-02-C-0031
, 02-C-0031, 5425, NCI-5425, NCT00030108
9.
Phase I Study of Cediranib in Pediatric Patients With Refractory or Recurrent Extracranial Malignant Solid Tumors or Acute Myeloid Leukemia
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
2 to 18
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
NCI-06-C-0152
, NCI-P6571, NCT00354848, ZENECA-D8480C00016
10.
Phase I Study of Lexatumumab With or Without Recombinant Interferon Gamma in Pediatric Patients With Relapsed or Refractory Solid Tumors or Lymphoma
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 30
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0040
, NCI-P6981, NCT00428272
11.
Phase I Study of Trabectedin in Pediatric Patients With Relapsed or Refractory Solid Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
4 to 16
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0054
, NCT00437047
12.
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Patients With Advanced or Refractory Solid Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
2 to 21
Sponsor:
NCI
Protocol IDs:
NCI-08-C-0007
, 08-C-0007, NCI-P6068, 7458, NCT00556881
13.
Phase I Study of Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes in Patients Undergoing Mismatched-Related or Phenotypically Similar Unrelated Donor Marrow Transplantation
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
BCM-H-6676
, H 6676, BCM-ETNA, NCT00608309
14.
Phase I Study of Total Marrow Irradiation With Helical Tomotherapy Image-Guided Intensity-Modulated Radiotherapy Followed by Alkylator-Intense Conditioning Comprising Busulfan, Melphalan, and Thiotepa and Autologous CD34+ Hematopoietic Progenitor Cell Transplantation in Patients With High-Risk or Relapsed Solid Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Diagnostic, Treatment
Status:
Active
Age:
70 and under
Sponsor:
NCI
Protocol IDs:
UMN-2005LS023
, UMN-2005LS023, UMN-MT2004-30, NCT00623077
15.
Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)
Phase:
No phase specified
Type:
Treatment
Status:
Active
Age:
Under 55
Sponsor:
Other
Protocol IDs:
561-2003
, NCT00231309
16.
New York Blood Center National Cord Blood Program
Phase:
No phase specified
Type:
Treatment
Status:
Active
Age:
not specified
Sponsor:
Other
Protocol IDs:
234
, NCT00212407
17.
Respiratory Tumor and Normal Tissue Motion
Phase:
No phase specified
Type:
Natural history/Epidemiology, Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
2003-0962
, NCT00415675
18.
Pilot Study of High-Dose Conditioning Chemotherapy Comprising Busulfan, Melphalan, and Topotecan Hydrochloride Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed or Relapsed Solid Tumors
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
6 months to 40
Sponsor:
NCI
Protocol IDs:
CHNMC-03112
, 03112, NCT00638898
19.
Intraosseous Infusion of Unrelated Cord Blood Grafts
Phase:
No phase specified
Type:
Treatment
Status:
Active
Age:
3 to 60
Sponsor:
Other
Protocol IDs:
Intraosseous Infusion
, NCT00967525
Select All on Page
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
